DUOCAINE (bupivacaine hydrochloride; lidocaine hydrochloride) by R-Pharm US is impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. Approved for regional anesthesia, analgesia for surgery, dental and 4 more indications. First approved in 2003.
Drug data last refreshed 1h ago · AI intelligence enriched 6d ago
DUOCAINE is a fixed-dose combination injectable local anesthetic containing bupivacaine hydrochloride and lidocaine hydrochloride. It works by blocking nerve impulse generation and conduction, increasing electrical excitation threshold and slowing action potential propagation. The product is indicated for regional anesthesia, surgical analgesia, dental procedures, and obstetrical use.
Product faces imminent loss of exclusivity with high competitive pressure (30/100); brand team likely prioritizes market defense and generic transition planning.
impulses, presumably by increasing the threshold for electrical excitation in the nerve, by slowing the propagation of the nerve impulse, and by reducing the rate of rise of the action potential. In general, the progression of anesthesia is related to the diameter, myelination, and conduction…
Worked on DUOCAINE at R-Pharm US? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/moDUOCAINE roles are concentrated in hospital-based sales, anesthesia-focused MSL work, and managed care navigation within R-Pharm US's smaller commercial footprint. Career opportunity is limited by zero linked jobs, suggesting modest team size and declining hiring.